Sign in Subscribe
Cancer treatment

New Findings in Non-Small Cell Lung Cancer Treatment Revealed in Phase 1b Study

Strategic Insights

— 1 min read

A recent phase 1b study published in the journal Clinical Cancer Research has shed new light on the treatment of advanced non-small cell lung cancer (NSCLC). Researchers from the University of Texas M.D. Anderson Cancer Center investigated the safety and efficacy of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab. The study involved 45 patients with unresectable NSCLC who received sequentially escalating doses of motesanib, carboplatin/paclitaxel, and/or panitumumab.

Key Takeaways:

  • The maximum tolerated dose (MTD) of motesanib was 125 mg once daily, with common adverse events including fatigue (60%), diarrhea (53%), hypertension (38%), anorexia (27%), and nausea (22%).
  • Three dose-limiting toxicities occurred: grade 4 pulmonary embolism and grade 3 deep vein thrombosis in patients receiving motesanib at 125 mg once daily.
  • The objective response rates were 17%, 0%, and 17% in arms A, B, and C, respectively.
  • Treatment with motesanib was tolerable when combined with carboplatin/paclitaxel and/or panitumumab, with little effect on motesanib pharmacokinetics at the 125-mg once daily dose level.
  • The study concluded that the 125-mg once daily dose of motesanib is being investigated in an ongoing phase 3 study in NSCLC.

Statistics:

  • 45 patients received motesanib in the study.
  • 3 dose-limiting toxicities occurred: 1 grade 4 pulmonary embolism and 2 grade 3 deep vein thrombosis.
  • Most common motesanib-related adverse events: fatigue (60%), diarrhea (53%), hypertension (38%), anorexia (27%), and nausea (22%).
  • Objective response rates: 17% in arms A and C, 0% in arm B.

Sources:

  • G.R. Blumenschein et al. (2010). Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clinical Cancer Research, 16(1), 279-90.
  • American Association Cancer Research. (2010). Clinical Cancer Research, Volume 16, Issue 1, January 2010.
  • G.R. Blumenschein, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 USA.
  • American Association Cancer Research, 615 Chestnut St., 17TH Floor, Philadelphia, PA 19106-4404, USA.

Read more